share_log

和黃醫藥：自願性公告－繼武田FRUZAQLA (呋喹替尼/fruquintinib) 銷售額超過2億美元和黃醫藥將收到首筆商業里程碑付款

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda

HKEX ·  Oct 31 16:31

Summary by Futu AI

和黄医药（HUTCHMED）宣布，其合作夥伴武田藥品工業（TSE：4502/ NYSE：TAK）將支付2000萬美元的商業里程碑付款，此次付款是基於轉移性結直腸癌治療藥物FRUZAQLA®（呋喹替尼）銷售額超過2億美元。這是和黄医药收到的首筆商業里程碑付款，標誌著其在中國境外商業化戰略上取得成功。FRUZAQLA®已在美國、歐盟、瑞士、加拿大、日本、英國、阿根廷、澳洲和新加坡等國家和地區獲批，並在其他多個國家和地區的監管申請進行中。和黃医药首席執行官兼首席科學官蘇慰國博士表示，此次里程碑付款將進一步鞏固公司的資產負債表，並期待擴展呋喹替尼的適應症範圍。結直腸癌是全球第三大常見癌症，和黃医药致力於發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。
和黄医药（HUTCHMED）宣布，其合作夥伴武田藥品工業（TSE：4502/ NYSE：TAK）將支付2000萬美元的商業里程碑付款，此次付款是基於轉移性結直腸癌治療藥物FRUZAQLA®（呋喹替尼）銷售額超過2億美元。這是和黄医药收到的首筆商業里程碑付款，標誌著其在中國境外商業化戰略上取得成功。FRUZAQLA®已在美國、歐盟、瑞士、加拿大、日本、英國、阿根廷、澳洲和新加坡等國家和地區獲批，並在其他多個國家和地區的監管申請進行中。和黃医药首席執行官兼首席科學官蘇慰國博士表示，此次里程碑付款將進一步鞏固公司的資產負債表，並期待擴展呋喹替尼的適應症範圍。結直腸癌是全球第三大常見癌症，和黃医药致力於發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。
HUTCHMED announced that its partner, Takeda Pharmaceutical (TSE: 4502/NYSE: TAK), will make a $20 million commercial milestone payment based on sales of the metastatic colorectal cancer treatment drug FRUZAQLA® (fruquintinib) exceeding $200 million. This is the first commercial milestone payment received by HUTCHMED, marking its success in overseas commercialization strategy in China. FRUZAQLA® has been approved in countries and regions including the USA, EU, Switzerland, Canada, Japan, United Kingdom, Argentina, Australia, and Singapore, with regulatory applications in progress in many other countries and regions. Dr. Weiguo Su, CEO and Chief Scientific Officer of HUTCHMED, stated that this milestone payment will further strengthen the company's balance sheet and looks forward to expanding the indications of fruquintinib. Colorectal cancer is the third most common cancer globally, and HUTCHMED is dedicated to discovering, globally developing, and commercializing targeted drugs and immunotherapies for cancer and immune diseases.
HUTCHMED announced that its partner, Takeda Pharmaceutical (TSE: 4502/NYSE: TAK), will make a $20 million commercial milestone payment based on sales of the metastatic colorectal cancer treatment drug FRUZAQLA® (fruquintinib) exceeding $200 million. This is the first commercial milestone payment received by HUTCHMED, marking its success in overseas commercialization strategy in China. FRUZAQLA® has been approved in countries and regions including the USA, EU, Switzerland, Canada, Japan, United Kingdom, Argentina, Australia, and Singapore, with regulatory applications in progress in many other countries and regions. Dr. Weiguo Su, CEO and Chief Scientific Officer of HUTCHMED, stated that this milestone payment will further strengthen the company's balance sheet and looks forward to expanding the indications of fruquintinib. Colorectal cancer is the third most common cancer globally, and HUTCHMED is dedicated to discovering, globally developing, and commercializing targeted drugs and immunotherapies for cancer and immune diseases.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated